Table 1.
Demographic and baseline characteristics of patients with mild and severe COVID-19 disease groups.
|
Mild disease (n=45) n (%) |
Severe disease (n=45) n (%) |
p |
|
|---|---|---|---|
|
Age (years), median (min-max) |
57 (23-90) |
64 (29-88) |
0.005* |
|
Sex (female) |
24 (53.3) |
26 (57.8) |
0.671† |
|
Length of stay in the hospital, median (min-max) |
9 (5-52) |
13 (7-51) |
<0.001* |
|
Death |
0 (0) |
6 (13.3) |
- |
|
Comorbidities | |||
|
Diabetes mellitus |
12 (26.7) |
24 (53.3) |
0.010† |
|
Hypertension |
21 (46.7) |
31 (68.9) |
0.033† |
|
Signs and symptoms | |||
|
Fever |
29 (64.4) |
28 (62.2) |
0.827† |
|
Cough |
33 (73.3) |
35 (77.8) |
0.624† |
|
Dyspnea |
24 (51.1) |
40 (88.9) |
<0.001† |
|
Myalgia |
34 (75.6) |
31(68.9) |
0.480† |
|
Fatigue |
33 (73.3) |
40 (88.9) |
0.059† |
|
Loss of appetite |
30 (66.7) |
39 (86.7) |
0.025† |
|
Loss of flavor |
15 (33.3) |
14 (31.1) |
0.822† |
|
Loss of smell |
18 (40.0) |
41 (91.1) |
<0.001† |
|
Thorax CT results | |||
|
Frosted glass |
45 (100) |
44 (97.8) |
- |
|
Infiltration |
21 (46.7) |
32 (71.1) |
0.018† |
|
Consolidation |
12 (26.7) |
17 (37.8) |
0.259† |
|
Involvement zones | |||
|
Upper |
4 (8.9) |
0 (0) |
- |
|
Lower |
5 (11.1) |
0 (0) |
- |
|
Lower & upper |
8 (17.8) |
3 (6.7) |
- |
|
Lower & middle |
12 (26.7) |
9 (20) |
- |
|
Whole |
16 (35.6) |
33 (73.3) |
<0.001 |
|
Bilateral |
41 (91.1) |
45 (100) |
- |
|
Intensive care |
1 (2.2) |
10 (22.2) |
0.004† |
|
Corticosteroid therapy |
22 (48.9) |
42 (93.3) |
<0.001† |
|
SpO2 | |||
|
<90 |
10 (22.2) |
44 (97.8) |
<0.001† |
|
O2 requirement (yes) |
25 (55.6) |
44 (97.8) |
<0.001† |
|
Non-rebreather mask (yes) |
2 (4.4) |
27 (60.0) |
<0.001† |
|
Mini-pulse methylprednisolone (oral, yes) |
1 (2.2) |
11 (24.4) |
0.002† |
* Mann-Whitney U test
† Pearson chi-square
Each superscript letter denotes a subset of clinic type categories whose column proportions do not differ significantly from each other at the 0.05 level. All patients included in the study were treated with favipiravir and low molecular weight heparin (LMWH).